Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

89P - Cold atmospheric plasma-activated fluids as a potential new intravesical agent for the treatment of bladder cancer

Date

21 Oct 2023

Session

Poster session 09

Topics

Basic Science;  Cancer Research

Tumour Site

Urothelial Cancer

Presenters

Maria Filomena Botelho

Citation

Annals of Oncology (2023) 34 (suppl_2): S187-S214. 10.1016/S0923-7534(23)01931-2

Authors

M.F. Botelho1, E. Tavares-da-Silva2, E. Pereira1, J. Craveiro3, L. Fernandes3, F. Caramelo1, A.M. Abrantes4, A.S. Pires1, A. Figueiredo5

Author affiliations

  • 1 Coimbra Institute For Clinical And Biomedical Research (icbr), Area Of Environment, Genetics And Oncobiology Research (cimago), Institute Of Biophysics, Faculty Of Medicine; Cibb; Cacc, Univ Coimbra, 3000-370 - Coimbra/PT
  • 2 Dept. Of Urology And Renal Transplantation, CHUC - Centro Hospitalar e Universitario de Coimbra - Hospital Geral, 3004-561 - Coimbra/PT
  • 3 Coimbra Institute For Clinical And Biomedical Research (icbr), Area Of Environment, Genetics And Oncobiology Research (cimago), Institute Of Biophysics, Faculty Of Medicine, Univ Coimbra, 3000-370 - Coimbra/PT
  • 4 Coimbra Institute For Clinical And Biomedical Research (icbr) Area Of Environment Genetics And Oncobiology (cimago), Biophysics Institute Of Faculty Of Medicine; Cibb; Cacc, Univ Coimbra, 3000-548 - Coimbra/PT
  • 5 Av Bissaya Barreto 299, CHUC - Centro Hospitalar e Universitario de Coimbra - Hospital Geral, 3041-801 - Coimbra/PT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 89P

Background

Cold atmospheric plasma (CAP) has been studied for cancer treatment. One of its forms, CAP activated liquids (CAPAL), may be an alternative to intravesical agents to treat bladder cancer (BC). The surgical bipolar resectoscope, when in use, is a source of thermal plasma (TP), which exerts effects on the surrounding sodium chloride solution for irrigation (NaCl 0.9%), transforming it into a TP activated liquid (TPAL), which is produced in very close contact with the bladder wall. To accelerate a possible introduction of plasma-activated liquid in the treatment of BC, we decided to compare the properties and biological effects of CAPAL and TPAL.

Methods

An electronic device was designed by our group to create CAP. TP was produced by a resectoscope. NaCl 0.9% was exposed to CAP or TP during short periods of time (30, 60, 120, 180 seconds) creating CAPAL or TPAL. The reactive oxygen and nitrogen species (RONS) activity was evaluated using the OxiSelect™ RONS Assay Kit in each activated liquid. BC cell lines, TCCSUP (grade IV) and HT-1376 (grade III), were incubated with CAPAL or TPAL. Metabolic activity was evaluated by MTT assay and protein content by SRB assay, 24h post-incubation.

Results

In comparison to non irradiated NaCl 0.9%, both CAPAL and TPAL, in all exposure times resulted in a significant rise in the activity of RONS. Regarding the biological activity of the activated liquids in the BC cell lines, both CAPAL and TPAL induced a decrease in cell metabolic activity and protein content in an exposure-time dependent manner. CAPAL induced a higher antitumor effect on the high-grade cell line (TCCSUP), while TPAL had a similar effect on both cell lines. Comparing the two activated liquids, CAPAL required longer exposure times to achieve the same effects observed with TPAL at lower exposure times.

Conclusions

This study shows that PAL can be a therapeutic agent for BC. Both TPAL and CAPAL showed similar biologics in BC cells. Currently, in clinical practice, TPAL is already in close contact with the bladder wall during surgery, however only briefly and diluted by irrigation. This work intends to get one step closer to demonstrate that CAPAL can be a safe and effective BC treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Foundation For Science And Technology (FCT), Portugal, through the Strategic Projects, UIDB/04539/2020, UIDP/04539/2020, and by COMPETE-FEDER, reference number POCI-01-0145-FEDER-007440. Scholarship grants from FCT and European Social Funding to E.P. (2021.05543. BD).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.